Körper Sixten, Seifried Erhard, Schrezenmeier Hubert
Institut für Klinische Tranfusionsmedizin und Immungenetik Ulm, Ulm, GERMANY.
Institut für Transfusionsmedizin und Immunhämatologie, DRK-Blutspendedienst Baden-Württemberg-Hessen, Frankfurt.
Dtsch Med Wochenschr. 2023 Mar;148(7):423-426. doi: 10.1055/a-2013-8775. Epub 2023 Mar 20.
Convalescent plasma was discussed as a therapeutic option early in the course of the COVID-19 pandemic. However, until the onset of the pandemic, only the results of mostly small single-arm studies in other infectious diseases were available, which did not prove efficacy. In the meantime, the results of more than 30 randomized trials of COVID-19 convalescent plasma (CCP) for treatment of COVID-19 are available 1. Despite the heterogeneity of the results, conclusions for an optimal use are possible.
在新冠疫情初期，康复期血浆被作为一种治疗选择进行了讨论。然而，在疫情爆发之前，仅有其他传染病的大多为小型单臂研究结果可用，这些研究并未证实其疗效。与此同时，目前已有30多项关于新冠康复期血浆（CCP）治疗新冠的随机试验结果 1 。尽管结果存在异质性，但仍有可能得出最佳使用方法的结论。
